Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 10Active not recruiting 6Completed 5Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 1Glioblastoma 1

Interventions

pembrolizumab 116Carboplatin 48Nivolumab 46Paclitaxel 35Cyclophosphamide 35Cisplatin 34Gemcitabine 30atezolizumab 25Specimen Handling 25venetoclax 24Pemetrexed 24Magnetic Resonance Spectroscopy 24fludarabine 22Ipilimumab 22Docetaxel 22Bevacizumab 22Biopsy 21Radiotherapy 20Azacitidine 20Fluorouracil 19Dexamethasone 19Radiosurgery 18durvalumab 17Leucovorin 16olaparib 14Trastuzumab 14Cetuximab 14Capecitabine 14fludarabine phosphate 13Lenalidomide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carmustine × 1 year × Clear all
NCT03382977 2026-05-08

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

VBI Vaccines Inc.

Phase 1/2 Terminated
70 enrolled
CNS

Glioblastoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡